Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Lab-Made antibody calm severe eczema?

NCT ID NCT06101823

Disease control Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing an experimental monoclonal antibody called OpSCF in adults with moderate to severe atopic dermatitis, also known as eczema. About 50 participants receive either OpSCF or a placebo injection every two weeks for 14 weeks. The main goal is to measure how much the Eczema Area and Severity Index changes from the start of the study to week 16, and to track side effects. After that, participants may join an extension phase where everyone receives OpSCF every four weeks for 40 more weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental monoclonal antibody called OpSCF
What this could lead to
If it works, OpSCF could offer another targeted option for adults whose moderate to severe eczema is hard to control.
What could go wrong
This is a small, early-stage trial of about 50 people, so any benefit seen may not hold up in larger studies. Monoclonal antibodies can cause infusion or injection reactions and other immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Nov 2023

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject has clinically confirmed diagnosis of active AD. * Subject has at least a 6-month history of AD * Subject is willing to use effective birth control Exclusion Criteria: * Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study. * Subject has any clinically significant medical condition that would put the subject at undue risk or interfere with interpretation of study results. * Subject has used dupilumab within 26 weeks prior to Day 1. * Subject has used tralokinumab within 12 weeks prior to Day 1. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Advanced Clinical Research Institute

    Tampa, Florida, 33607, United States

  • Arlington Dermatology

    Rolling Meadows, Illinois, 60008, United States

  • Axon Clinical Research

    Inglewood, California, 90301, United States

  • Cahaba Dermatology & Skin Health Center

    Birmingham, Alabama, 33607, United States

  • Centre de Recherche Saint-Louis

    Québec, Quebec, G1W 4R4, Canada

  • DS Research of Kentucky

    Louisville, Kentucky, 40241, United States

  • Dermatology Of Seattle

    Bellevue, Washington, 98004, United States

  • First OC Dermatology Research

    Fountain Valley, California, 92708, United States

  • Forest Hills Dermatology Group

    Kew Gardens, New York, 11415, United States

  • Innovaderm Research Inc

    Montreal, Quebec, H2X 2V1, Canada

  • Oakland Hills Dermatology P.C

    Auburn Hills, Michigan, 48326, United States

  • Options Research Group

    West Lafayette, Indiana, 47906, United States

  • Oshawa Clinic Dermatology Trials

    Oshawa, Ontario, L1H 1B9, Canada

  • RM Medical Research

    Miami Lakes, Florida, 33014, United States

  • Research Toronto

    Toronto, Ontario, M4W 2N2, Canada

  • Rodgers Dermatology

    Frisco, Texas, 75034, United States

  • Saginaw Bay Dermatology

    Bay City, Michigan, 48706, United States

  • Skin Cancer and Dermatology Institute

    Reno, Nevada, 89509, United States

  • Skin Care Research

    Boca Raton, Florida, 33456, United States

  • Skin Research of South Florida

    Miami, Florida, 33173, United States

  • Unison Clinical Trials

    Sherman Oaks, California, 91403, United States

  • University Clinical Trials

    San Diego, California, 92123, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.